VANCOUVER, British Columbia, April 15, 2004 (PRIMEZONE) -- ProtoKinetix Inc. (OTCBB:PKTX), announces today that it has received a preliminary report from their new Director of Medical Research in Paris. Dr. Jean-Marie Dupuis reports that the preliminary results of the third-party validation trials on the RECAF(tm) molecule being conducted by the Georges Pompidou Hospital are "very positive." Dr. Dupuis further reported that "the labeling of the malignant cells is strong and clear with a nice delineation between malignant and normal cells."
Dr. John Todd, president and CEO of ProtoKinetix Inc., is traveling this week to meet with the Department of Pathology at the Georges Pompidou Hospital in Paris to review the results with some of the top medical scientists in Europe, including members of the ProtoKinetix Scientific Advisory Board. They will advise Dr. Todd of their plan to complete the trials over the next month. Dr. Todd will also be meeting with the members of the ProtoKinetix Scientific Advisory Board to start the development process for the antibodies to this RECAF receptor site.
About ProtoKinetix:
ProtoKinetix Inc. is a therapeutic development company whose mission is to develop effective biological therapeutics for the treatment of malignancies. The company is focused on the research, development and utilization of a new generation of monoclonal antibodies termed "Super-Antibodies." These antibodies are engineered to provide higher potency and resiliency resulting in vastly enhanced therapeutic impact. ProtoKinetix is using this technology to create therapeutic antibodies, ultimately in an effort to help in the treatment of cancer.
Safe Harbor
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission (www.sec.gov), including the Company's recently filed Form 10KSB.
On behalf of the Board of Directors,
Dr. John Todd President